FIGURE 1.

Clinical characteristics of patients treated with HER2 inhibitors and distribution of adverse event reporting rates. (A) Visualization of overlapping relationships between users of different HER2 inhibitors and the total number of all HER2 inhibitors reported in different countries was based on the R packages UpSetR and ggplot2. (B) Number and percentage of cases of each HER2 inhibitor in monotherapy and combination therapy. Considering that the total number of pyrotinib was too small, they were excluded from monotherapy and combination therapy statistics. (C) Heat map displays the distribution of adverse event reporting rates for seven HER2 inhibitors.